Master of Science
Dr. Joseph L. Chin and Dr. Nicholas Power
Currently available screening tests for prostate cancer (PCa) are neither very sensitive nor specific. Microparticles (MP) are submicron tumor cell fragments released by PCa cells into the circulation and offer a possible means of sampling the tumor. We evaluated the utility of a MP blood test using nanoscale flow cytometry to distinguish patients with PCa from patients with benign prostatic hyperplasia (BPH). We used monoclonal antibodies against prostate specific membrane antigen, gastrin releasing peptide receptor and ghrelin peptide ligand.
We found higher but statistically insignificant, PSMA and Ghrelin dual +ve MP counts in the BPH group. Our results show that although MP can be enumerated, better more exclusive surface antigens and different antibodies, are required to test the utility of MP for this to be used as a "Next Generation Screening Tool" for PCa. In addition, comparison with a more suitable control group would improve accuracy of the experimental test.
Siddiqui, Khurram M., "Prostate Cancer Microparticles as a Next Generation Screening Tool for Prostate Cancer" (2014). Electronic Thesis and Dissertation Repository. 2641.